Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics

Research output: Contribution to journalReviewpeer-review

  1. A new Cochrane review on electronic cigarettes for smoking cessation: should we change our practice?

    Research output: Contribution to journalLetterpeer-review

  2. The search for the "healthy" blood eosinophil count

    Research output: Contribution to journalEditorialpeer-review

  3. World No Tobacco Day: smoking, nicotine and children

    Research output: Contribution to journalEditorialpeer-review

  4. EAN/ERS/ESO/ESRS statement on the impact of sleep disorders on risk and outcome of stroke

    Research output: Contribution to journalJournal articlepeer-review

View graph of relations

Monoclonal antibody therapies have significantly improved treatment outcomes for patients with severe asthma; however, a significant disease burden remains. Available biologic treatments, including anti-immunoglobulin (Ig)E, anti-interleukin (IL)-5, anti-IL-5Rα and anti-IL-4Rα, reduce exacerbation rates in study populations by approximately 50% only. Furthermore, there are currently no effective treatments for patients with severe, type 2-low asthma. Existing biologics target immunological pathways that are downstream in the type 2 inflammatory cascade, which may explain why exacerbations are only partly abrogated. For example, type 2 airway inflammation results from several inflammatory signals in addition to IL-5. Clinically, this can be observed in how fractional exhaled nitric oxide ( F eNO), which is driven by IL-13, may remain unchanged during anti-IL-5 treatment despite reduction in eosinophils, and how eosinophils may remain unchanged during anti-IL-4Rα treatment despite reduction in F eNO The broad inflammatory response involving cytokines including IL-4, IL-5 and IL-13 that ultimately results in the classic features of exacerbations (eosinophilic inflammation, mucus production and bronchospasm) is initiated by release of "alarmins" thymic stromal lymphopoietin (TSLP), IL-33 and IL-25 from the airway epithelium in response to triggers. The central, upstream role of these epithelial cytokines has identified them as strong potential therapeutic targets to prevent exacerbations and improve lung function in patients with type 2-high and type 2-low asthma. This article describes the effects of alarmins and discusses the potential role of anti-alarmins in the context of existing biologics. Clinical phenotypes of patients who may benefit from these treatments are also discussed, including how biomarkers may help identify potential responders.

Original languageEnglish
Book seriesEuropean Respiratory Journal. Supplement
Issue number5
Publication statusPublished - 12 Nov 2020

ID: 60627395